This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Vély, F. et al. Nat. Immunol. 17, 1291–1299 (2016).
Weinkove, R., Filbey, K. & Le Gros, G. Nat. Immunol. 17, 1237–1238 (2016).
Mace, E. M. & Orange, J. S. Front. Immunol. 7, 545 (2016).
Mace, E. M. et al. J. Clin. Immunol. 37, 1–74 (2017).
Fehniger, T. A., Cooper, M. A. & Harnessing, N. K. Trends Immunol. 37, 877–888 (2016).
Malmberg, K. J. et al. Semin. Immunol. 31, 20–29 (2017).
Holmes, T. D. & Bryceson, Y. T. Semin. Immunol. 28, 368–376 (2016).
Khakoo, S. I. et al. Science 305, 872–874 (2004).
Martin, M. P. & Carrington, M. Immunol. Rev. 254, 245–264 (2013).
Imai, K., Matsuyama, S., Miyake, S., Suga, K. & Nakachi, K. Lancet 356, 1795–1799 (2000).
Kamili, Q. U. A. et al. J. Allergy Clin. Immunol. 134, 1451–1453 (2014).
Laffort, C. et al. Lancet 363, 2051–2054 (2004).
T.A.F. is a member of the scientific advisory board for Cyto-Sen Therapeutics and receives research funding from Celgene, Affimed and Altor BioScience.
About this article
Cite this article
Orange, J.S., Mace, E.M., French, A.R. et al. Comment on: Evidence of innate lymphoid cell redundancy in humans. Nat Immunol 19, 788–789 (2018). https://doi.org/10.1038/s41590-018-0164-5
This article is cited by
Journal of Clinical Immunology (2020)
Nature Immunology (2018)